# U05 Bootstrap Controlled Amendment Decision Independent Design Review v0.1

Target PR: #127
Reviewed exact head: 42484959ae5d5c434027a74a019a6919ee42aef1

## Verdict

    U05 Bootstrap Controlled Amendment Decision
    Independent Design Review
    = REVISE_REQUIRED

    BF-U05-BOOTSTRAP-IR-01
    = PHASE5_AND_PHASE9_AMENDMENT_IMPACT_OMITTED
    = OPEN / BLOCKING

    BF-U05-BOOTSTRAP-IR-02
    = BUSINESS_OWNER_DEFINED_BUT_EXECUTABLE_UNIT_HOST_UNDEFINED
    = OPEN / BLOCKING

    BF-U05-BOOTSTRAP-IR-03
    = CANDIDATE_B_AMENDMENT_SCOPE_IS_OVERGENERALIZED
    = OPEN / BLOCKING

    BF-U05-BOOTSTRAP-IR-04
    = PRE_D03_F3_ASSESSMENT_CAN_CREATE_PARALLEL_GAP_TRUTH
    = OPEN / BLOCKING

    RQ-U05-BOOTSTRAP-IR-05
    = SEPARATE_BOOTSTRAP_AND_READY_POLICY_DECISIONS
    = OPEN / REQUIRED

    Controlled Amendment Decision Package
    = NOT_READY_FOR_OWNER_SELECTION_YET

    Upstream amendment = NOT_AUTHORIZED
    OD-U05-BOOTSTRAP-01 = NOT_READY_FOR_DECISION
    OD-U05-READY-01 = SEPARATE OWNER POLICY DECISION / NOT_APPROVED

## Accepted direction

    bootstrap gap = controlled upstream amendment
    Owner approval != amendment != re-review != implementation authorization
    one G2/U05 Clinical Readiness resolver
    no completeness shortcut
    no null-gap -> READY
    no LLM final readiness decision
    changed frozen artifacts must be re-reviewed and re-frozen

## Required remediation

1. Add Phase 5 and Phase 9 to the explicit amendment-impact inventory.
2. For every candidate/subcandidate define semantic owner, executable Unit host, Scheduler position, trigger, contracts, commit boundary, capability usage, idempotency and failure owner.
3. Split Candidate B into existing-source semantic extension vs genuinely new readiness source domain.
4. Candidate A must use one canonical F3 Gap lifecycle; no standalone pre-D03 sufficiency side-channel.
5. Keep bootstrap architecture decision separate from OD-U05-READY-01 and bind READY approval to the exact post-amendment input model/policy version.

No implementation, frozen upstream amendment, routing, production, release activation, or real-patient authorization is granted.